Physician profile
Michael D Chesnut
NPI 1821127333
$8,240.13
in general payments reported to CMS, 2019-2025
40 companies · $866 in 2025
The $866 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $759 · 2020: $1,312 · 2021: $1,542 · 2022: $1,209 · 2023: $1,421 · 2024: $1,131 · 2025: $866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,402 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,401.69 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $883.81 | 2019-2025 | Trintellix, Gattex |
| Abbvie INC. | $821.11 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Amgen INC. | $781.14 | 2019-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $664.26 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $661.20 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $653.38 | 2019-2025 | |
| Lilly USA, LLC | $460.18 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $409.97 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $356.92 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $297.76 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $294.18 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $219.88 | 2024-2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company Ltd. | $162.78 | 2022 | |
| Axsome Therapeutics, INC. | $149.82 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $142.19 | 2019-2021 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $137.99 | 2020-2024 | Nexletol |
| Grifols USA, LLC | $124.97 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.29 | 2020-2024 | Ofev |
| Astrazeneca Pharmaceuticals Lp | $105.79 | 2021-2025 | Farxiga, Breztri |
| Astellas Pharma US INC | $98.07 | 2019-2025 | Veozah |
| Currax Pharmaceuticals LLC | $63.89 | 2020-2023 | Contrave |
| Eisai INC. | $61.89 | 2021-2025 | |
| Sanofi Pasteur INC. | $61.44 | 2019-2024 | |
| Abbott Laboratories | $59.16 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $54.50 | 2019-2022 | |
| Bausch Health US, LLC | $51.40 | 2020-2025 | Wellbutrin |
| Merck Sharp & Dohme LLC | $37.44 | 2021-2025 | Capvaxive, Gardasil 9 |
| Exact Sciences Corporation | $36.04 | 2023-2025 | Cologuard Collection Kit |
| Medtronic Vascular, INC. | $34.44 | 2020 | |
| Inspire Medical Systems, INC. | $34.26 | 2024 | Inspire |
| Medtronic, INC. | $31.59 | 2023 | Intellis Adaptivestim |
| Ardelyx, INC. | $27.71 | 2025 | Ibsrela |
| Qiagen, LLC | $23.71 | 2022 | |
| Antares Pharma, INC. | $20.50 | 2025 | Xyosted |
| Averitas Pharma INC. | $19.40 | 2023 | Qutenza |
| Bayer Healthcare Pharmaceuticals INC. | $16.38 | 2021 | |
| Lucid Diagnostics INC. | $15.86 | 2022 | |
| Genentech USA, INC. | $14.72 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.42 | 2019 | |
| Allergan, INC. | $12.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Chesnut listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.